ZURICH (dpa-AFX) - The major Swiss bank UBS has started the valuation of Schott Pharma shares with a "Neutral" rating and a target price of 40 euros. The packaging and delivery specialist for injectable drugs is a first-class company, wrote analyst Olivier Calvet in a study published on Tuesday. However, opportunities and risks are currently balanced. With a view to the booming topic of weight loss pills from the GLP-1 drug class, he sees more earnings potential in the direct competition./ag/gl

Publication of the original study: 13.05.2024 / 16:43 / GMT First dissemination of the original study: 13.05.2024 / 16:43 / GMT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------